TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31523279
Drug: Empirical amoxicillin-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical amoxicillin-containing bismuth quadruple therapy
Study: 31524342
Drug: ATX-101 (deoxycholic
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATX-101 (deoxycholic acid) 2 mg/cm2
Study: 31525774
Drug: Blood cultures
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood cultures obtained before initiation of antimicrobial treatment
Study: 31525774
Drug: Blood cultures
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood cultures obtained within 120 minutes after initiation of antimicrobial treatment
Study: 31527689
Drug: Plasma EBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma EBV DNA-negative patients (0-20 copies/ml)
Study: 31527689
Drug: Plasma EBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma EBV DNA-positive patients (>20 copies/ml)
Study: 31527875
Drug: Antiretroviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral treatment (ART) interruption
Study: 31528838
Drug: DASH diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DASH diet + Captopril (CAP) 25 mg
Study: 31528838
Drug: Control (CON)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (CON) diet + Captopril (CAP) 25 mg
Study: 31529018
Drug: Chemoradiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy with a simultaneous integrated boost of radiotherapy dose (50.4 Gy to subclinical areas at risk and 63.0 Gy to the gross tumor and involved nodes, all given in 28 fractions) with concurrent docetaxel and capecitabine or fluorouracil
Study: 31529070
Drug: Sodium depletion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium depletion test (oral administration of 40 mg of furosemide under low sodium diet)
Study: 31529136
Drug: Lower limb
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower limb injections of abobotulinumtoxinA (1,000 U or 1,500 U)
Study: 31529136
Drug: Lower and
Normalized name: Flower and weed pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower and upper limb injections of abobotulinumtoxinA (1,000 U lower limb, 500 U upper limb)
Study: 31530099
Drug: Artificial intelligence
Normalized name: Intelence
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artificial intelligence fitting for cochlear implants
Study: 31530099
Drug: Manual fitting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual fitting for cochlear implants
Study: 31532724
Drug: Pembrolizumab 2
Normalized name: pembrolizumab 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 2 mg/kg every 3 weeks for up to 24 months
Study: 31532833
Drug: Pembrolizumab (anti-PD-1),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (anti-PD-1), administered as part of a Phase II clinical trial, with biopsies taken at baseline and 15-21 days post-dose.
Study: 31533771
Drug: Denosumab administered
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab administered subcutaneously at 1 mg/kg body weight, dosage scheduled based on urinary deoxypyridinoline levels.
Study: 31534013
Drug: AZD0156 (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0156 (low doses)
Study: 31534192
Drug: G-CSF +
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF + plerixafor (G-CSF + P)
Study: 31534773
Drug: Maximal strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal strength training (MST) twice a week for 5 weeks, consisting of 3-4 sets of 4-6 repetitions at ≥85% of 1RM in a squat exercise.
Study: 31534773
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) doing regular pre-season preparations.
Study: 31537486
Drug: Ruxolitinib (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib (15 mg twice a day) on a continuous 28-day cycle
Study: 31537565
Drug: Lipid injectable
Normalized name: Lipid Injectable Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid injectable emulsion (two doses)
Study: 31537565
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control (no treatment)
Study: 31538078
Drug: Ramosetron (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron (0.3 mg IV)
Study: 31538230
Drug: Lapatinib (750,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (750, 1000, 1250, or 1500 mg daily) plus Bortezomib (0.7, 1.0, 1.3, or 1.6 mg/m²)
Study: 31538815
Drug: Dose-escalation followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-escalation followed by an expansion cohort
Study: 31541204
Drug: Matched-related bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched-related bone marrow (BM) grafts with single-agent PTCy
Study: 31541381
Drug: Cabozantinib 60-mg
Normalized name: cabozantinib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 60-mg daily on a 21-day cycle + trastuzumab every 3 weeks (Cohort 1)
Study: 31541381
Drug: Cabozantinib 60-mg
Normalized name: cabozantinib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 60-mg daily on a 21-day cycle (Cohort 2)
Study: 31541381
Drug: Cabozantinib 60-mg
Normalized name: cabozantinib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 60-mg daily on a 21-day cycle (Cohort 3)
Study: 31541381
Drug: Cabozantinib 60-mg
Normalized name: cabozantinib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 60-mg daily on a 21-day cycle
Study: 31541945
Drug: Oral panobinostat
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral panobinostat plus chemotherapy (idarubicin and cytarabine)
Study: 31541945
Drug: Idarubicin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin and cytarabine (chemotherapy)
Study: 31544817
Drug: MEDI4276 (antibody-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4276 (antibody-drug conjugate)
Study: 31544947
Drug: Treatment (surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (surgery or medical treatment)
Study: 31545113
Drug: Selinexor in
Normalized name: Product containing selinexor in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor in combination with decitabine
Study: 31548621
Drug: Blood pressure-lowering
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure-lowering treatment based on absolute cardiovascular risk
Study: 31548863
Drug: Strategies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strategies to manage stress and promote healthy pregnancy targets (e.g., prenatal care)
Study: 31549155
Drug: 30-mg oral
Normalized name: dacomitinib 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-mg oral dose of primaquine (PQ)
Study: 31549262
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bleeding risk scores and frailty scales
Study: 31551193
Drug: SCTE-AI 75
Normalized name: AI-128
DrugBank: AI-128 (DB05841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCTE-AI 75 mg once weekly for 6 weeks, adjusted to 50 mg or 100 mg as needed.
Study: 31551193
Drug: SCTE-AI 75
Normalized name: AI-128
DrugBank: AI-128 (DB05841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCTE-AI 75 mg once weekly for 6 weeks, adjusted to maintain T trough levels.
Study: 31551349
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg OXi4503
Study: 31551349
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg OXi4503
Study: 31551349
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg OXi4503
Study: 31551376
Drug: HCV Treatment
Normalized name: THCV
DrugBank: Tetrahydrocannabivarin (DB11755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV Treatment as Prevention (TasP) in Tayside, Scotland
Study: 31551902
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no specific treatment other than psychoeducation, n=46
Study: 31552641
Drug: Ipragliflozin 50-mg
Normalized name: canagliflozin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipragliflozin 50-mg tablet once daily for 24 weeks
Study: 31553487
Drug: Dasatinib at
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib at 50 mg daily
Study: 31553639
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (IC) with cisplatin and fluorouracil followed by concurrent chemoradiotherapy (CCR) with three cycles of cisplatin.
Study: 31553639
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (IC) with cisplatin and fluorouracil followed by concurrent chemoradiotherapy (CCR) with two cycles of cisplatin (amended treatment).
Study: 31555109
Drug: tDCS (anodal;
Approvals — FDA: no, EMA: no, PMDA: no
Description: tDCS (anodal; F3, cathodal, Fp2, 2A, 20 min) twice daily for five consecutive days
Study: 31555487
Drug: (Neo) adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Neo) adjuvant chemotherapy
Study: 31555522
Drug: Apatinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (250 mg per day)
Study: 31556778
Drug: Home pregnancy
Normalized name: Home Pregnancy Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home pregnancy test G
Study: 31558424
Drug: Neratinib 240
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neratinib 240 mg orally once a day for 7 to 21 days preoperatively, resumed postoperatively in 28-day cycles.
Study: 31558424
Drug: Neratinib (preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neratinib (preoperative and postoperative administration).
Study: 31558467
Drug: Ublituximab (NHL:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ublituximab (NHL: 900 mg; CLL: 600 or 900 mg) + Umbralisib (800 or 1200 mg)
Study: 31558469
Drug: GSI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSI treatment
Study: 31558469
Drug: GSI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSI treatment in MM tumor-bearing NOD/SCID/γc-/- mice
Study: 31558469
Drug: Short-term GSI
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term GSI administration to MM patients
Study: 31558479
Drug: INVAC-1 (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: INVAC-1 (100, 400, and 800 μg) administered intradermally followed by electroporation or by Tropis, a needle-free injection system
Study: 31558626
Drug: Lung cancer
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung cancer screening by low-dose computed tomography (LDCT)
Study: 31558670
Drug: ORH-2014 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORH-2014 5 mg
Study: 31558670
Drug: ORH-2014 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORH-2014 10 mg
Study: 31558670
Drug: ORH-2014 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORH-2014 15 mg
Study: 31558804
Drug: Ixazomib-thalidomide-dexamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib-thalidomide-dexamethasone (4 mg, day 1, 8, 15; 100 mg daily; and 40 mg weekly) for eight cycles followed by ixazomib maintenance for one year
Study: 31558804
Drug: Ixazomib maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib maintenance therapy
Study: 31560055
Drug: Antiviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral treatment (oseltamivir)
Study: 31560741
Drug: E/C/F/TAF (150/150/200/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: E/C/F/TAF (150/150/200/10 mg once daily)
Study: 31560741
Drug: E/C/F/TDF (150/150/200/300
Approvals — FDA: no, EMA: no, PMDA: no
Description: E/C/F/TDF (150/150/200/300 mg once daily)
Study: 31560935
Drug: SM08502 (CLK
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM08502 (CLK inhibitor), orally administered
Study: 31562530
Drug: Intranasal inoculation
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal inoculation with nonattenuated, wild-type Bordetella pertussis strain B1917; dose escalated from 10^3 to 10^5 colony-forming units.
Study: 31562530
Drug: Azithromycin administered
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin administered from Day 14.
Study: 31562873
Drug: Robot-assisted gait
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted gait training and physical therapy
Study: 31563412
Drug: Cetuximab-RT plus
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab-RT plus avelumab (10 mg/kg Q2W + 4 months maintenance)
Study: 31563880
Drug: Regional anesthesia
Normalized name: ACL6SP45 REGIONAL ANESTHESIA KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional anesthesia (RA) administered within 7 days after injury
Study: 31563880
Drug: No regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No regional anesthesia (RA) administered
Study: 31564038
Drug: Conventional imaging
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional imaging (computed tomography and somatostatin receptor scintigraphy)
Study: 31566105
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with low-density lipoprotein cholesterol ≥1 g/L
Study: 31566438
Drug: CCR2 antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CCR2 antagonist (CCR2A)
Study: 31566438
Drug: Combined CCR2
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined CCR2 antagonist (CCR2A) and angiotensin-converting enzyme inhibitor (ACEi)
Study: 31567472
Drug: Kaolin-maximum rate
Normalized name: Kaolin
DrugBank: Kaolin (DB01575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaolin-maximum rate of thrombus generation using G (K-MRTGG)
Study: 31567472
Drug: Functional fibrinogen-maximum
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional fibrinogen-maximum rate of thrombus generation using G (FF-MRTGG)
Study: 31567573
Drug: Intra-operative fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-operative fentanyl dosing
Study: 31570103
Drug: Current-metformin-users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current-metformin-users
Study: 31570103
Drug: Never-metformin-users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Never-metformin-users
Study: 31570103
Drug: Prediabetic never-metformin-users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediabetic never-metformin-users
Study: 31570488
Drug: Eltrombopag initiated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag initiated at 50 mg/day, maximum 150 mg/day
Study: 31570517
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg daily on days 4 to 10 of each 14-day cycle with mFOLFOX6 (5-fluorouracil, leucovorin, and oxaliplatin)
Study: 31570781
Drug: G-CSF +
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF + plerixafor (G + P)
Study: 31570781
Drug: G-CSF +
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF + plerixafor + chemotherapy (G + P + C)
Study: 31570822
Drug: HRDetect-high patients
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRDetect-high patients on adjuvant chemotherapy
Study: 31571945
Drug: Dexlansoprazole modified
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole modified release-based therapy (DACM)
Study: 31571945
Drug: Lansoprazole-based therapy
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole-based therapy (Control)
Study: 31571977
Drug: Tramadol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (2 mg/kg bolus)
Study: 31572288
Drug: Simulation-based training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulation-based training for rapid evaluation and management of acute stroke; details on dosage and duration not available.
Study: 31573078
Drug: Subcutaneous rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous rituximab plus standard induction chemotherapy for DLBCL or FL for 4-7 cycles, and/or every 2 months maintenance monotherapy for FL for 6-12 cycles.
Study: 31573746
Drug: Response-adapted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Response-adapted therapy with rituximab, bendamustine, mitoxantrone, and dexamethasone (RBMD)
Study: 31573980
Drug: rosuvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin (20 mg/d × 28 days)
Study: 31574863
Drug: Laser meridian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser meridian massage (3 times weekly for 4 weeks)
Study: 31575939
Drug: Intravenous enzyme
Normalized name: alpha-D-galactosidase enzyme Chewable Tablet [Beano]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous enzyme replacement therapy (IV-ERT) for 2 years
Study: 31576162
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ibuprofen + 100 mg caffeine
Study: 31576684
Drug: BLS-M07 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLS-M07 (500 mg, 1,000 mg, and 1,500 mg administered orally, 5 times a week on weeks 1, 2, 4, and 8)
Study: 31576684
Drug: BLS-M07 (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLS-M07 (1,000 mg administered orally in phase 2a)
Study: 31578012
Drug: Rivaroxaban treatment
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban treatment in patients with prior ischemic stroke/TIA
Study: 31578012
Drug: Rivaroxaban treatment
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban treatment in patients without prior ischemic stroke/TIA
Study: 31578311
Drug: Gene-corrected autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene-corrected autologous cell therapy (transplanted epidermal sheets measuring 5 × 7 cm)
Study: 31578311
Drug: Gene-corrected autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene-corrected autologous cell therapy
Study: 31579027
Drug: BTG-002814 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTG-002814 (100 mg vandetanib) delivered transarterially, 7 to 21 days before surgery
Study: 31579027
Drug: BTG-002814 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTG-002814 (100 mg vandetanib)
Study: 31580386
Drug: nab-paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel plus gemcitabine plus cisplatin (25 mg/m2, 37.5 mg/m2, 50 mg/m2) on days 1 and 8 of a 21-day cycle
Study: 31582553
Drug: Yttrium-90-labeled anti-CD45
Normalized name: yttrium
DrugBank: Yttrium Y-90 (DB13076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yttrium-90-labeled anti-CD45 antibody followed by fludarabine and 2 Gy total body irradiation prior to hematopoietic cell transplantation
Study: 31582673
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy in SP group (67.5% prescribed)
Study: 31582673
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy in PP group (30.1% prescribed)
Study: 31582673
Drug: Reasons for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reasons for treatment discontinuation
Study: 31583561
Drug: Supraphysiologic doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supraphysiologic doses of levothyroxine (L-T4)
Study: 31584000
Drug: iCBT (internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: iCBT (internet-based cognitive behavioral therapy) program for 9 weeks
Study: 31584608
Drug: Crizotinib 250
Normalized name: crizotinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib 250 mg twice daily in c-MET ≥6 copies cohort
Study: 31584608
Drug: Crizotinib 250
Normalized name: crizotinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib 250 mg twice daily in c-MET mutation cohort
Study: 31584608
Drug: Crizotinib 250
Normalized name: crizotinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib 250 mg twice daily in ROS-1 translocation cohort
Study: 31585957
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) and selective hedgehog pathway inhibitor vismodegib
Study: 31586664
Drug: Concurrent cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Concurrent cetuximab (400 mg/m2) and intensity modulated radiation therapy with carbon ion boost
Study: 31586757
Drug: Glembatumumab vedotin
Normalized name: Glembatumumab vedotin
DrugBank: Glembatumumab vedotin (DB05996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glembatumumab vedotin (GV) 1.9 mg/kg/dose administered on day 1 of each 21 day cycle.
Study: 31586998
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in patients <70 years old
Study: 31586998
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in patients ≥70 years old
Study: 31587882
Drug: Lazertinib (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazertinib (20 mg, 40 mg, 80 mg, 120 mg, 160 mg, 240 mg, or 320 mg once daily continuously in 21-day cycles)
Study: 31588493
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg liposomal amphotericin B
Study: 31588493
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg liposomal amphotericin B
Study: 31588493
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of 300 or 500 mg liposomal amphotericin B for patients ≥100 kg
Study: 31588567
Drug: Pomalidomide 4
Normalized name: pomalidomide 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide 4 mg plus low-dose dexamethasone (40 mg or 20 mg for patients aged >75 years)